A Phase 1, Open Label, Single Arm Study To Establish The Safety Of Administering CP 675,206 As A One Hour Infusion In Patients With Surgically Incurable Stage III Or Stage IV Melanoma
This study was prematurely discontinued on April 28, 2008 because a concomitant Phase 3
study met pre-specified futility criteria. The decision to close enrollment early was not
based on any safety concerns.
Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
To assess safety and tolerability during and for 1 hour following a 15 mg/kg dose of CP 675,206 administered as a one hour infusion.
Last patient dosed = 31Dec2009
United States: Food and Drug Administration
|Research Site||Mesa, Arizona|
|Research Site||Anaheim, California|
|Research Site||Boulder, Colorado|
|Research Site||Albany, Georgia|
|Research Site||Bloomington, Indiana|
|Research Site||Ashland, Kentucky|
|Research Site||Asheville, North Carolina|